These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 18327427

  • 1. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia.
    Lee PI, Wu MH, Huang LM, Chen JM, Lee CY.
    J Microbiol Immunol Infect; 2008 Feb; 41(1):54-61. PubMed ID: 18327427
    [Abstract] [Full Text] [Related]

  • 2. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
    Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ.
    Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
    [Abstract] [Full Text] [Related]

  • 3. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
    Kogan R, Martínez MA, Rubilar L, Payá E, Quevedo I, Puppo H, Girardi G, Castro-Rodriguez JA.
    Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
    [Abstract] [Full Text] [Related]

  • 4. [Importance of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia].
    Sáez-Llorens X, Castaño E, Wubbel L, Castrejón MM, de Morales I, Vallarino D, de Atencio I, Muñiz L, Olsen K, McCracken GH.
    Rev Med Panama; 1998 Sep; 23(2):27-33. PubMed ID: 11214557
    [Abstract] [Full Text] [Related]

  • 5. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.
    Block S, Hedrick J, Hammerschlag MR, Cassell GH, Craft JC.
    Pediatr Infect Dis J; 1995 Jun; 14(6):471-7. PubMed ID: 7667050
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P, MOXIRAPID Study Group.
    Clin Infect Dis; 2005 Dec 15; 41(12):1697-705. PubMed ID: 16288390
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
    Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM.
    Curr Med Res Opin; 2004 Apr 15; 20(4):555-63. PubMed ID: 15119993
    [Abstract] [Full Text] [Related]

  • 12. Comparative tolerability, safety and efficacy of tablet formulations of twice-daily clarithromycin 250 mg versus once-daily extended-release clarithromycin 500 mg in pediatric and adolescent patients.
    Block SL.
    Clin Pediatr (Phila); 2006 Sep 15; 45(7):641-8. PubMed ID: 16928842
    [Abstract] [Full Text] [Related]

  • 13. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial.
    Cascio A, Colomba C, Antinori S, Paterson DL, Titone L.
    Clin Infect Dis; 2002 Jan 15; 34(2):154-8. PubMed ID: 11740701
    [Abstract] [Full Text] [Related]

  • 14. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia in Istanbul, Turkey.
    Somer A, Salman N, Yalçin I, Ağaçfidan A.
    J Trop Pediatr; 2006 Jun 15; 52(3):173-8. PubMed ID: 16627487
    [Abstract] [Full Text] [Related]

  • 15. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections.
    Principi N, Esposito S, Blasi F, Allegra L, Mowgli study group.
    Clin Infect Dis; 2001 May 01; 32(9):1281-9. PubMed ID: 11303262
    [Abstract] [Full Text] [Related]

  • 16. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O.
    J Antimicrob Chemother; 2007 Jul 01; 60(1):112-20. PubMed ID: 17537866
    [Abstract] [Full Text] [Related]

  • 17. Mycoplasma pneumoniae and Chlamydia pneumoniae chronic cough in children: efficacy of clarithromycin.
    Velissariou IM, Papadopoulos NG, Giannaki M, Tsolia M, Saxoni-Papageorgiou P, Kafetzis DA.
    Int J Antimicrob Agents; 2005 Aug 01; 26(2):179-80. PubMed ID: 16023330
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC, Badaró R, Bumroongkit C, Mera JR, Dolmann AL, Juárez Martínez LG, Mayrinck LR, Tamez R, Yang JY.
    Clin Ther; 2003 May 01; 25(5):1453-68. PubMed ID: 12867221
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of Mycoplasma and Chlamydia pneumonia in severe community-acquired pneumonia among hospitalized children in Thailand.
    Samransamruajkit R, Jitchaiwat S, Wachirapaes W, Deerojanawong J, Sritippayawan S, Prapphal N.
    Jpn J Infect Dis; 2008 Jan 01; 61(1):36-9. PubMed ID: 18219132
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.